NON SMALL CELL LUNG CANCER

This study is testing a drug called alectinib, combined with standard chemotherapy, for people with early-stage lung cancer that can be surgically removed. It aims to see if giving this combination before or after surgery is safe and helps prevent the cancer from coming back. The…

This study is testing if a blood test that looks for tiny pieces of cancer DNA can help doctors decide when it might be safe for patients to stop their immunotherapy. It involves 39 people with advanced melanoma or non-small cell lung cancer whose cancer is under control after at…

This early-stage trial is testing whether a new experimental drug called RO7496353 is safe and effective when combined with existing immunotherapy and chemotherapy. The study involves 102 people with advanced lung, stomach, or pancreatic cancers that have spread and are considere…

This early-stage study is testing a new oral medication called HBI-2376 in people with advanced solid tumors that have specific KRAS or EGFR mutations. The main goals are to find the highest safe dose of the drug and to understand how the body absorbs and processes it. The trial …

This large, late-stage study is comparing a new two-drug combination plus chemotherapy against the current standard treatment for people with newly diagnosed, advanced non-small cell lung cancer that has spread. The main goal is to see if the new combination helps patients live l…

This study is testing whether adding very high doses of vitamin C (given through an IV) to standard chemotherapy and radiation treatment helps people with non-small cell lung cancer. All 43 participants will receive the vitamin C infusion along with their usual cancer therapy. Re…

This study is testing an experimental drug called SKB264, given alone or in combination with other therapies, for people with advanced or spreading non-small cell lung cancer. The main goals are to see if the treatment is safe and if it can shrink tumors. The trial will enroll ab…

This large, late-stage study is testing whether adding a new immunotherapy drug (nogapendekin alfa inbakicept) to standard first-line treatments can better control advanced non-small cell lung cancer. It is enrolling over 1,500 adults who have not yet received treatment for their…

This study is testing whether combining an approved immunotherapy drug (tislelizumab) with new experimental drugs, with or without standard chemotherapy, can better control advanced non-small cell lung cancer. It will enroll 400 patients who have not yet received treatment for th…

This study is testing whether adding a drug called alirocumab to standard pre-surgery treatment (chemotherapy plus an immunotherapy drug, cemiplimab) can help the immune system better recognize and attack early-stage non-small cell lung cancer. About 126 patients with stage 1B-3A…

This study is testing whether using two targeted drugs together is safe and effective for controlling advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. It is for adults who have not yet received any treatment for their advance…

This study is testing whether a combination of three investigational drugs is safe and effective for people with advanced non-small cell lung cancer whose disease has progressed after prior immunotherapy. The trial will enroll about 30 participants to see if the three drugs worki…

This study aims to find the safest and most effective dose of a precise, high-dose radiation treatment called SBRT for lung tumors located near major airways and blood vessels. It will enroll 30 patients with early-stage non-small cell lung cancer to carefully test increasing rad…

This early-stage trial is testing a new drug called INBRX-106, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how …

This study is testing whether adding a second drug (oleclumab) to an existing immunotherapy (durvalumab) can better control advanced lung cancer that cannot be surgically removed. It involves 30 adults in Russia whose cancer has not worsened after completing standard chemoradiati…

This global study is testing whether taking a daily pill called osimertinib for three years can prevent early-stage lung cancer from returning after surgery. It involves 390 adults whose lung cancer has been completely removed and has a specific genetic marker (EGFR mutation). Pa…

This is the first human study testing the safety and early effects of an experimental drug called BL-M17D1 in people with advanced cancers that have a specific marker called HER2. The trial will enroll 120 adults with various hard-to-treat cancers, including breast, lung, and sto…

This study is testing a new oral drug, JDQ443, against the standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It's for adults whose cancer has worsened after trying standard treatments like pl…

This study is testing an oral medication called selpercatinib (LOXO-292) for people with advanced solid tumors that have a specific genetic change in the RET gene. The goal is to find a safe dose and see if the drug can shrink these difficult-to-treat cancers. It is for patients …

This large, late-stage trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation works better for people with a specific type of advanced lung cancer that cannot be surgically removed. The study involves 328 patients worldwide and co…

This study provides continued access to the lung cancer drug lorlatinib for patients who are already benefiting from it in previous Pfizer trials. It allows 76 participants with specific genetic types of non-small cell lung cancer (ALK-positive or ROS1-positive) to keep receiving…

This early-stage trial is testing a new oral drug called zongertinib for people with advanced solid tumors, mainly non-small cell lung cancer, that have specific changes in the HER2 gene. The first part aims to find the highest safe dose. The second part will see if the drug can …

This study is testing whether adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer. Sixty participants will be randomly assigned to receive either real acupuncture or a sham (fake) acupuncture treatment during their f…

This is a first-in-human trial testing a new drug called BI-1910, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have worsened after standard treatments. The main goals are to find a safe dose, check for side eff…

This study is comparing a new targeted drug called selpercatinib to standard chemotherapy and immunotherapy for people with advanced lung cancer that has a specific genetic change called a RET fusion. The goal is to see if selpercatinib is more effective at controlling the cancer…

This is the first time a new drug called DS-1062a is being tested in people. The main goal is to find a safe and tolerable dose for patients with advanced solid tumors, including lung and breast cancers, that have not responded to standard treatments. The study will also test if …

This large, late-stage study is testing whether a drug called atezolizumab can help prevent non-small cell lung cancer from returning after patients have had surgery and chemotherapy. The trial will compare giving atezolizumab for about a year to providing only best supportive ca…

This study is testing several targeted drugs and immunotherapies for adults with advanced non-small cell lung cancer (NSCLC). It uses a simple blood test to find specific cancer markers and match patients to the most promising treatment for their cancer type. The main goals are t…

This study is testing a new oral drug, ARRY-614, to see if it can make standard immunotherapy drugs (nivolumab and ipilimumab) work better for people with advanced cancers. The first part checks the safety and best dose. The second part will see how well the combinations work to …

This study is testing whether adding a new drug called uliledlimab to standard immunotherapy and chemotherapy works better for advanced lung cancer patients who haven't had prior treatment. About 150 patients with stage IIIB-IV non-small cell lung cancer will receive either the n…

This study is testing an oral medication called BDTX-1535 for adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor) that have specific genetic changes. The goal is to find the safest and most effective dose and see if the drug can shrink tumors, …

This study is testing whether adding an older drug called DFMO to the immunotherapy pembrolizumab can help control advanced lung cancer in people whose tumors have a specific genetic change (STK11 mutation). The first part finds the safest dose, and the second part checks if the …

This early-stage clinical trial is testing a new experimental drug called RO7247669 in people with advanced solid tumors that have spread. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. The …

This study is testing an investigational drug called telisotuzumab vedotin for people with advanced non-small cell lung cancer (NSCLC) that has a specific biomarker called c-Met and has worsened after prior treatments. The goal is to see if the drug is safe and effective at contr…

This study is testing a new drug called divarasib against two existing drugs (sotorasib or adagrasib) for people with a specific type of advanced lung cancer (KRAS G12C-positive NSCLC) that has worsened after prior treatment. The main goal is to see if divarasib can better contro…

This study is testing whether giving an extra, targeted dose of radiation to the most active parts of a lung tumor can improve treatment results. It compares standard chemoradiation to the same treatment with this added 'boost.' The main goal is to see if this approach reduces th…

This early-stage study is testing a new oral drug called sunvozertinib (DZD9008) in people with advanced non-small cell lung cancer that has specific mutations in the EGFR or HER2 genes and has worsened after standard treatments. The main goals are to find a safe dose, understand…

This early-stage study is testing the safety of a new cancer drug called sacituzumab tirumotecan in Japanese patients. The drug is being given alone and in combination with an existing immunotherapy (pembrolizumab) to people with advanced solid tumors or a specific type of advanc…

This study aimed to test the safety and effectiveness of a two-drug combination (Ezabenlimab and BI 907828) for people with advanced, hard-to-treat cancers that had spread. It was designed for adults with specific types of soft tissue sarcoma, lung, breast, colorectal, or biliary…

This study is testing whether adding an immunotherapy drug called durvalumab to a precise form of radiation therapy (SBRT) works better than radiation alone for early-stage lung cancer. It is for patients with a higher risk of their cancer returning who are not candidates for sur…

This global Phase 3 trial is testing whether new drug combinations given after surgery can prevent early-stage lung cancer from returning. The study compares two experimental treatments against standard care in patients who have had their tumor completely removed but are at highe…

This study is testing whether adding two drugs (amivantamab and bevacizumab) to a continued targeted therapy (lazertinib) can help control advanced lung cancer that has started growing again after previous treatment. It will involve about 60 patients with a specific genetic chang…

This early-stage trial is testing a new drug called RC148, given alone or with other treatments, for people with advanced non-small cell lung cancer that has spread. The main goals are to see if the drug is safe and if it helps shrink or control tumors. The study will involve abo…

This study aims to see if a new drug called ensartinib works better and is safer than the standard drug crizotinib for people with a specific type of advanced lung cancer (ALK-positive NSCLC). It will involve about 290 adults who have had up to one prior chemotherapy treatment. T…

This study is testing if adding a new drug called relatlimab to a standard treatment (nivolumab plus chemotherapy) works better for people with advanced or recurrent non-small cell lung cancer. It will involve about 468 adults who have not yet received treatment for their advance…

This study is testing whether a new drug called tobemstomig, when given with standard chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer who haven't had treatment before. It will inv…

This is the first human study of an experimental oral medication called HBI-2438 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find the highest safe dose and understand how the body processes the drug. The study …

This study compared two drug approaches for people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation and has worsened after standard chemotherapy. 453 participants were randomly assigned to receive either the experimental drug abem…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study is testing whether adding an experimental drug called SI-B001 to standard chemotherapy can help control advanced non-small cell lung cancer that has worsened despite prior immunotherapy. It involves about 69 adults whose cancer has specific genetic markers (EGFR and AL…

This study is comparing two treatment strategies for adults with advanced non-small cell lung cancer (NSCLC) that has a high level of a specific protein (PD-L1). It tests whether starting with a combination of immunotherapy (pembrolizumab) and chemotherapy is better at delaying c…

This early-stage study is testing the safety of a new cancer drug called PF-08046032, both by itself and combined with another drug called sasanlimab. It involves a small group of adults with advanced or spreading cancers, including certain lymphomas and solid tumors like lung ca…

This early-stage study is testing whether adding a new drug called amivantamab to standard targeted therapies can help control advanced lung cancer that has started growing again. It will involve about 12 adults whose cancer has specific genetic changes and has become resistant t…

This study directly compares two types of minimally invasive surgery for early-stage lung cancer: robotic-assisted surgery and standard video-assisted (keyhole) surgery. Researchers are testing which method leads to better quality of life for patients after surgery, fewer complic…

This study is testing whether adding a new investigational drug called SI-B001 to an existing lung cancer medication (osimertinib) is safe and effective for people with advanced non-small cell lung cancer that has worsened after prior treatment. It aims to find the best dose of t…

This study is testing whether adding a second drug, cobimetinib, to the standard drug alectinib can help control advanced lung cancer that has stopped responding to alectinib alone. Researchers want to find the safest dose of this combination and see if it can shrink tumors or sl…

This study is testing whether adding an immunotherapy drug called tislelizumab to standard chemotherapy, given both before and after surgery, works better than chemotherapy alone for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor before surger…

This is the first study in people for a new drug called Amivantamab, designed to fight advanced non-small cell lung cancer by targeting two specific proteins on cancer cells. The main goals are to find safe doses when given alone, with another drug (lazertinib), or with standard …

This study is testing whether combining two existing drugs, nivolumab and ramucirumab, can help control advanced lung cancer that has grown again after a patient's prior immunotherapy. It will enroll 36 adults with this specific type of cancer to see if the combination is safe an…

This study is testing whether combining three existing drugs—nivolumab, ipilimumab, and nintedanib—is safe and effective for people with advanced non-small cell lung cancer (NSCLC). It will enroll about 66 adults whose cancer has spread and has no curative treatment options. The …

This study tests a new program designed to improve teamwork between cancer specialists and primary care doctors (PCPs) for patients who have both cancer and a heart-related condition like high blood pressure or diabetes. The goal is to see if better coordination helps manage the …

This study is testing whether adding a new drug called savolitinib to a patient's current lung cancer medication (osimertinib) can help control the cancer after it has started growing again. It will involve about 30 adults with a specific type of advanced lung cancer. Patients wi…

This study is comparing a new drug called SKB264 against standard chemotherapy for people with advanced non-small cell lung cancer. It's for patients whose cancer has a specific genetic change (EGFR mutation) and has continued to grow despite initial targeted therapy. The trial a…

This study is testing a three-drug combination (Lazertinib, Pemetrexed, and Carboplatin) for people with a specific type of advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after being treated with the drug Lazertinib alone. The main …

This early-stage study is testing whether combining two targeted drugs, amivantamab and tepotinib, can help control advanced non-small cell lung cancer that has specific changes in a gene called MET. The main goals are to find a safe dose for the combination and to get an early l…

This study is testing if adding a drug called thymosin alpha 1 helps people with a specific type of advanced lung cancer complete a full year of follow-up immunotherapy. The immunotherapy is given after initial chemotherapy and radiation. Researchers will compare two groups of pa…

This study is testing a new oral medication called AB-106 for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1 fusion. The trial aims to find the best dose and see how safe and effective the drug is for 173 patients, including those w…

This study is testing whether the drug osimertinib can help prevent lung cancer from coming back after surgery. It is for patients with a specific, less common type of genetic mutation in their cancer. The goal is to see if taking this pill after surgery helps patients stay cance…

This early-stage study is testing a new drug called DCC-3116, both by itself and combined with other cancer drugs, for people with advanced solid tumors that have specific genetic changes. The main goals are to find safe doses and see if the treatments can shrink tumors. It is fo…

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200301. It is being tested alone and in combination with an existing drug (tislelizumab) in adults with advanced solid tumors who have already tried other treatments. The main goal is to see ho…

This study is testing whether adding a new drug called fianlimab to a standard treatment (cemiplimab + chemotherapy) works better for people with advanced non-small cell lung cancer (NSCLC). It will involve about 950 patients who have not yet received treatment for their advanced…

This early-stage study is testing whether combining two existing cancer drugs (abemaciclib and pembrolizumab) is safe and might help control advanced lung cancer or hormone-positive breast cancer. It will enroll about 100 people with these specific cancer types who meet strict he…

This study is testing a new immunotherapy drug called PF-06801591 in people with advanced cancers that have spread. The first part finds a safe dose for patients in Asia with various solid tumors. The second part tests the drug's effect specifically in people with advanced non-sm…

This study is testing a drug called entrectinib for people with advanced solid tumors that have specific genetic changes (NTRK, ROS1, or ALK gene rearrangements). It's a 'basket trial,' meaning it groups patients by their tumor's genetic type rather than where the cancer started …

This study is testing whether giving immunotherapy drugs before surgery is safe and can help shrink tumors in patients with operable non-small cell lung cancer. It involves 39 participants who will receive one or two immunotherapy drugs, or a combination of immunotherapy and chem…

This study is testing a precise form of radiation therapy for people with early-stage lung cancer who also have a serious lung-scarring disease (ILD) and cannot have surgery. The goal is to see if this targeted radiation can help patients live longer while keeping side effects ma…

This study is comparing a new oral drug, PLB1004, to standard platinum-based chemotherapy for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR exon 20 insertion. The main goal is to see if PLB1004 is better at controlling t…

This is the first human study testing a new cancer drug called AB248, either alone or combined with an existing immunotherapy (pembrolizumab). The trial aims to find safe doses and see if the treatment shows early signs of helping adults with advanced solid tumors that have sprea…

This study is comparing a new targeted drug, DZD9008, against standard platinum-based chemotherapy as the first treatment for adults with advanced non-small cell lung cancer that has a specific genetic mutation (EGFR exon 20 insertion). The main goal is to see if the new drug can…

This early-stage study is testing whether combining two existing cancer drugs—ceritinib and docetaxel—can help control advanced lung cancer that has stopped responding to standard chemotherapy. The trial aims to find the safest dose of this combination and see if it can shrink tu…

This early-stage trial is testing an experimental drug called BL-M02D1 in adults with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The study first aims to find a safe and effective dose, then checks if the drug ca…

This study is testing whether combining two immunotherapy drugs (zimberelimab and domvanalimab) can help control advanced non-small cell lung cancer in people who haven't had prior treatment. The trial is for patients whose cancer has high levels of a specific marker called PD-L1…

This study is testing a combination of two drugs, encorafenib and binimetinib, for Chinese adults with a specific advanced form of lung cancer (BRAF V600E mutated NSCLC). The main goals are to see how well the drugs shrink tumors and to monitor their safety. The trial is for pati…

This study is testing if giving an immunotherapy drug called durvalumab before and after surgery can help control non-small cell lung cancer. It involves 25 patients with operable cancer. The main goal is to see how much the drug shrinks the tumor before it is removed and to unde…

This study is testing if adding targeted radiation to the standard first-line treatment (chemotherapy plus immunotherapy) helps people with advanced non-small cell lung cancer live longer. It aims to see if radiation can boost the immune system's ability to fight cancer throughou…

This study is testing whether combining a drug called durvalumab (an immunotherapy) with radiation therapy can help control locally advanced non-small cell lung cancer. It is for patients who are not eligible for the standard treatment of chemotherapy followed by radiation, often…

This study is testing a treatment plan for people with a type of lung cancer that might be removable by surgery. Participants first receive a combination of immunotherapy (durvalumab) and standard chemotherapy. Doctors then decide if surgery or radiation is best, followed by more…

This study is testing if a new drug called SKB264 works better when combined with the standard immunotherapy drug pembrolizumab for people with advanced non-small cell lung cancer. It's for patients who haven't had any prior treatment for their advanced cancer and whose tumors ha…

This early-stage study is testing a new drug called RNDO-564, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced cancers that have stopped responding to standard treatments. The main goals are to find safe doses and see how the bod…

This large international study is testing whether adding one of two new drugs to an existing immunotherapy helps control advanced lung cancer longer. It's for adults with Stage III non-small cell lung cancer that cannot be surgically removed and has not worsened after completing …

This early-stage study is testing a new oral drug called KIN-2787 in adults with advanced solid tumors that have specific BRAF or NRAS gene mutations, including lung cancer and melanoma. The main goals are to find a safe dose, see how the body processes the drug, and get an early…

This study is testing a new two-drug combination for people with a specific type of advanced lung cancer that has gotten worse after standard treatments. The goal is to see if the combination can shrink tumors and control the cancer. Researchers will also closely monitor the safe…

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200603. It will be tested alone and in combination with an existing drug, tislelizumab, in 83 adults with advanced solid tumors like lung, kidney, or skin cancer. The main goal is to check for …

This is the first study in people to test the safety and early effectiveness of an investigational drug called ABBV-400 for adults with advanced solid tumors that have stopped responding to standard treatments. The study will find the best dose of ABBV-400 given alone and will al…

This is an early-stage study to test the safety and find the right dose of a new drug called PF-08046049/SGN-BB228. It is for adults with advanced solid tumors, including melanoma, lung, colorectal, pancreatic cancer, or mesothelioma, that have stopped responding to standard trea…

This study is testing a new drug called BL-B01D1 against standard chemotherapy for people with advanced non-small cell lung cancer. It's for patients whose cancer has continued to grow despite treatment with EGFR-targeted drugs. The goal is to see if the new drug can better contr…

This study is testing a new way to deliver radiation therapy for advanced non-small cell lung cancer. It uses real-time MRI scans to guide and adjust the radiation beams during treatment, aiming to target the tumor more precisely while better protecting healthy lung tissue. The g…

This study is testing a new oral drug called AZD5305 to see if it is safe and can help control advanced cancers. It is being tested alone and in combination with other cancer medicines in over 700 patients with various hard-to-treat solid tumors. The main goals are to find the ri…

This study is for people with a specific type of advanced lung cancer that has spread to the brain. After initial treatment with targeted drugs, if only a few small brain tumors remain, the trial tests whether adding a very precise form of radiation (stereotactic radiotherapy) ca…

This study is testing if using two drugs, osimertinib and gefitinib, together works better than one alone for people newly diagnosed with a specific type of advanced lung cancer (EGFR mutation). The main goal is to see if this combination can control the cancer for longer by tryi…

This is a first-in-human study testing a new type of cancer treatment called P-MUC1C-ALLO1 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how well the body tolerates this 'off-the-shelf' CAR-T …

This study is testing whether adding the drug hydroxychloroquine (used for malaria and arthritis) to the cancer drug erlotinib helps control advanced non-small cell lung cancer for a longer period. It involves 76 adults with a specific genetic mutation in their cancer who have no…

This was a special access program for the drug capmatinib. It was designed for patients with a specific, advanced form of non-small cell lung cancer who had no other treatment options and could not join a standard clinical trial. The program provided the drug outside of a trial s…

This study is testing a new combination of cancer drugs for people with advanced non-small cell lung cancer that has spread and lacks certain genetic targets. It aims to see if adding the drug sacituzumab govitecan to standard treatments (pembrolizumab with or without chemotherap…

This study aims to find the best treatment approach for patients with non-small cell lung cancer that has spread to the brain in a limited way (fewer than 5 spots). Researchers are comparing two strategies: treating the main tumor and brain spots directly versus using body-wide m…

This study is for people with advanced non-small cell lung cancer whose cancer started growing again outside the brain after initial treatment with osimertinib. It tests whether continuing osimertinib while adding standard chemotherapy works better and controls the cancer longer …

This study is for people with advanced non-small cell lung cancer that has continued to grow despite receiving both chemotherapy and immunotherapy. Researchers want to see if adding a drug called atezolizumab to a standard two-drug combination (paclitaxel and bevacizumab) can hel…

This study is testing a new combination treatment for people with advanced lung cancer, melanoma, kidney cancer, or head and neck cancer that has stopped responding to standard immunotherapy. The treatment involves three parts: a targeted radiation dose to one tumor, injections o…

This study is testing personalized drug combinations for people with a specific type of advanced lung cancer (Stage III NSCLC) that cannot be removed by surgery. It aims to see if adding new targeted drugs to standard treatment can better control the cancer and prevent it from sp…

This study is testing a new drug called BL-B01D1, both by itself and combined with an existing lung cancer drug (osimertinib), for people with advanced non-small cell lung cancer. The main goals are to find the safest and most effective dose and to see how well the treatment shri…

This early-stage study is testing a new drug called BT5528 in people with advanced solid tumors that have spread or returned. The main goals are to find a safe dose, understand the side effects, and see if the drug shows early signs of helping to control cancers like ovarian, lun…

This study is testing an oral medication called taletrectinib for people with advanced lung cancer that has a specific genetic change called ROS1. The trial aims to see how well the drug shrinks tumors and how safe it is for patients, including those who have or haven't had simil…

This study is testing if a targeted drug called brigatinib works better alone or when combined with two chemotherapy drugs for people with advanced lung cancer that has a specific genetic change (ALK-positive). About 110 patients who haven't had treatment for their advanced cance…

This study is testing whether a new drug called DS-1062a works better than the standard chemotherapy drug docetaxel for people with advanced non-small cell lung cancer that has worsened after previous treatments. It will involve about 605 adults whose cancer has spread and who ha…

This study is testing several different drug combinations for people with advanced non-small cell lung cancer whose cancer has continued to grow despite receiving standard immunotherapy. The trial aims to find new treatment options for this group of patients who currently have li…

This study is testing if adding standard chemotherapy to a targeted pill (osimertinib) works better than the pill alone for people with a specific type of advanced lung cancer. It enrolled about 587 adults whose cancer has a common genetic change called an EGFR mutation. The goal…

This study is testing a new combination of two or three drugs for people with a specific type of lung cancer (KRAS G12C Non-Small Cell Lung Cancer). It aims to see if the combination is safe and effective, especially for patients whose cancer has progressed after previous treatme…

This study is testing a new personalized vaccine treatment for people who have had surgery for non-small cell lung cancer. The goal is to see if the vaccine, given with an immune-boosting drug, can train the body's immune system to recognize and attack any remaining cancer cells …

This study is testing whether a new drug called SHR-A2009 works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to their initial targeted therapy. About 500 adults …

This trial is testing if a powerful combination of immunotherapy, chemotherapy, and precise radiation can control advanced lung cancer that has spread to only a few other body sites. The goal is to stop the cancer from progressing further and improve survival. About 96 patients w…

This study is testing the safety of adding a new immunotherapy drug (MPDL3280A) to the standard treatment of chemotherapy and radiation for patients with non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this three-part combination is safe and ca…

This study is testing a three-drug combination for adults with advanced small cell or non-small cell lung cancer whose initial treatment is no longer working. The first part of the study aims to find the safest and most effective dose. The second part will see how well this combi…

This is an early-stage trial to test the safety and determine the right dose of a new experimental drug called LY4066434. The drug is designed to block a common cancer-driving protein called KRAS in people with advanced solid tumors, including pancreatic, lung, and colorectal can…

This study tested whether combining two targeted drugs (tepotinib and osimertinib) could help control advanced non-small cell lung cancer that had developed resistance to osimertinib alone. It enrolled 140 adults whose cancer had a specific genetic change called MET amplification…

This study is testing a new, simpler way to give an existing lung cancer drug. It compares giving the drug as an under-the-skin injection versus the standard method of an IV infusion. The main goals are to see if the injection gets similar drug levels into the body and is as safe…

This study is testing a drug called T-DXd (Trastuzumab deruxtecan) for people with a specific type of advanced lung cancer that has spread to the brain. The main goal is to see how well the drug can delay the growth of cancer in the brain. It will also monitor for serious side ef…

This study is testing whether adding a new drug called uliledlimab to an existing immunotherapy (toripalimab) works better than standard single-drug immunotherapies for advanced non-small cell lung cancer. It will enroll 450 adults with previously untreated cancer that has spread…

This study is for people with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation). It tests if adding two chemotherapy drugs (carboplatin and pemetrexed) to the standard targeted drug osimertinib works better than taking osimertinib alone. The t…

This study is testing if combining two existing cancer drugs, pembrolizumab and vorinostat, is safe and works better than pembrolizumab alone for people with advanced lung cancer that has spread. It will involve about 120 adults whose cancer has progressed after at least one prio…

This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tum…

This study is testing whether an immunotherapy drug called atezolizumab can help people with advanced non-small cell lung cancer who haven't had chemotherapy yet. The trial includes 60 patients whose cancer has spread (stage IV) and shows high levels of a protein called PD-L1. Re…

This study is testing a multi-step treatment for people with stage II or III non-small cell lung cancer. It combines precise, high-dose radiation to the main tumor with standard chemotherapy and radiation to nearby lymph nodes, followed by an immunotherapy drug. The main goal is …

This study is testing new drug combinations for people with advanced solid tumors that have a specific genetic change called KRAS G12C. It focuses on patients with non-small cell lung cancer or colorectal cancer who have already tried standard treatments. The main goals are to fi…

This early-stage trial is testing the safety and effectiveness of a modified virus (VSV-IFNβ-NIS) when given alongside standard immunotherapy drugs (like pembrolizumab or nivolumab/ipilimumab). It is for adults with specific advanced solid tumors—including non-small cell lung can…

This study is testing whether a combination of two targeted drugs, encorafenib and binimetinib, can help control advanced non-small cell lung cancer that has a specific genetic change called BRAF V600E. It is for adults whose cancer has spread and who have either had no prior tre…

This large study is testing whether the drug pembrolizumab can help prevent early-stage lung cancer from returning after surgery. It involves over 1,100 patients who have had their cancer surgically removed and completed standard chemotherapy. Participants receive either the acti…

This early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …

This study is testing a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. It compares this new drug, which works by blocking two different cancer pathways at once, to standard immunotherapy drugs. The main goal is to see if the new drug is b…

This study is testing whether having a team of experts review a patient's unique tumor genetics leads to better care than the usual approach. It involves 659 people with advanced non-small cell lung cancer who are starting treatment. The main goals are to see if this personalized…

This study is testing whether using a precise, high-dose radiation treatment on a few new or growing tumors can help people with advanced lung or breast cancer stay on their current medications longer. It aims to see if this approach can delay the cancer from getting worse. The t…

This study is for adults with a specific type of advanced lung cancer (non-small cell) that has a mutation in the EGFR gene. It aims to see if adding a drug called ramucirumab to the standard drug osimertinib can help control the cancer for a longer time without it getting worse.…

This is an early-stage study to find a safe dose and see how the body processes a new drug called GDC-6036. It is being tested alone and with other cancer drugs in people with advanced solid tumors, like lung or colorectal cancer, that have a specific genetic change called KRAS G…

This is an early safety study testing a new cancer vaccine called PeptiCRAd-1, given alongside the immunotherapy drug pembrolizumab. It aims to see if this combination is safe and can activate the immune system to fight cancer in patients with advanced solid tumors that have stop…

This study is testing whether a targeted drug called sunvozertinib can shrink tumors in people with a specific type of lung cancer before they have surgery. It is for adults with stage II-IIIB non-small cell lung cancer that has a particular genetic change called an EGFR exon 20 …

This study is testing whether a blood test, called a liquid biopsy, can help people with advanced lung cancer start treatment faster. It compares the time it takes to get results from this blood test versus the standard method of testing a piece of the tumor. The goal is to see i…

This study is testing a new lab technique called OSNA to see if it's better at finding tiny amounts of cancer cells in lymph nodes removed during robotic lung cancer surgery. It will compare the new method to the standard way of checking lymph nodes under a microscope. The goal i…

This study looks back at past PET/CT scans from 500 lung cancer patients to see if artificial intelligence (AI) can spot hidden patterns. The goal is to build computer models that can help doctors better stage the cancer, predict its genetic type, and estimate a patient's surviva…

This study is testing a new artificial intelligence (AI) tool designed to help doctors treat lung cancer that has spread to the brain. The tool analyzes standard brain MRI scans to predict whether a patient's cancer has specific genetic markers (EGFR or ALK), which determine the …

This study aims to find the best way to collect tissue samples during a lung cancer biopsy to ensure there is enough material for advanced genetic testing. It will compare taking two needle passes versus three passes from suspicious lymph nodes. The study will also test if a simp…

This study is testing whether two types of PET-CT scans can accurately predict if non-small cell lung cancer has spread to nearby lymph nodes before a patient has surgery. Researchers at Fudan University are enrolling 280 patients with early-stage lung cancer to compare the scan …

This study is testing if giving a drug called trilaciclib before standard chemotherapy can protect patients' bone marrow and reduce severe side effects like infections and anemia. It will enroll about 40 adults with advanced non-small cell lung cancer. The main goal is to see if …

This study observes how heart function changes in lung cancer patients receiving combined chemotherapy, radiation, and immunotherapy. Researchers measure heart performance during walking tests to see if these measurements can predict treatment side effects and survival outcomes. …

This study aims to understand the types of bacteria living in the lungs, airways, and gut of people with non-small cell lung cancer. Researchers will compare samples from 40 patients, half of whom receive chemotherapy before surgery and half who have surgery alone. The goal is to…

This study aims to learn if simple blood tests can predict how well patients with lung or kidney cancer will respond to immunotherapy drugs. Researchers will collect blood and stool samples from 100 patients receiving standard immunotherapy treatment to look for patterns. The goa…

This study is observing how doctors use a blood test called VeriStrat to help decide on treatments for patients with a common type of lung cancer. It involves over 5,000 patients and aims to see if the test results help predict which treatments work better for different people. T…

This study is screening cancer patients to collect genetic information from their tumors and saliva. Researchers will analyze this data to identify patients who might qualify for future clinical trials testing new cellular therapies. No treatment is provided in this study—it's pu…

This study aims to help doctors choose the best future treatments for patients with advanced cancers. Researchers are analyzing stored tumor samples from over 3,000 patients to look for specific genetic markers. The goal is to create a personalized profile for each patient's canc…

This study is observing how well the immunotherapy drug atezolizumab works and its safety for patients with advanced lung, bladder, or liver cancer in real-world medical settings. It involves over 2,700 patients who are already receiving this drug as part of their standard care. …

This study aims to understand how well the targeted drug osimertinib works for patients with advanced lung cancer in real-world French hospitals, not just in controlled trials. It will follow about 274 patients who have a specific genetic mutation (EGFR) and are starting osimerti…

This study observes how 1,500 Russian patients with advanced lung cancer are treated in routine clinical practice. Researchers will collect data on what treatments doctors prescribe and how often they test for specific cancer biomarkers. The goal is to understand current treatmen…

This study aims to understand how common a specific DNA repair problem is in people with a certain type of advanced lung cancer (EGFR-mutated NSCLC). Researchers will look at tissue samples from 100 patients to see if having this problem is linked to how patients fare and if it m…

This study collects blood and tumor cells from cancer patients and blood from healthy volunteers. The cells are used in the lab to support research into future immune cell therapies for cancers like melanoma, breast cancer, and lung cancer. No treatment is given in this study; it…

This study aims to understand how advanced lung cancer is treated in real-world settings across nine countries. Researchers will analyze existing medical records from 800 patients to learn about treatment patterns and survival outcomes. The study does not involve new treatments o…